NEW YORK, Jan. 11, 2023 (GLOBE NEWSWIRE) — MiNK Therapeutics, Inc.a clinical-stage biopharmaceutical company pioneering the discovery, development and commercialization of allogeneic, off-the-shelf, invariant natural T-killer cell (iNKT) therapies for the treatment of cancer and other immune-mediated diseases, announced that Dr. Jennifer Buell, President and CEO of MiNK, will take part in a fireside chat on March 3approx Annual B. Riley Securities Oncology Conference on Jan. 18that 11:00 a.m. ET.
Access to Live Fireplace Chat is available at https://brileyoncology22.sequireevents.com/. After the fireside chat, a recording will be available on the Events and Presentations page of the MiNK website at https://investor.minktherapeutics.com/events-and-presentations.
B. Riley Securities 3rd Annual Oncology Conference, January 18-19, will feature over 30 SMiD-Cap healthcare companies focused on the development and commercialization of new drugs and key technologies, spanning multiple next-generation therapeutic modalities. The conference features KOL panel discussions featuring leading scientists and industry leaders at the forefront of ongoing translational and clinical research in novel immunotherapies, cell therapies and targeted oncology approaches, as well as imaging and radiation oncology initiatives aimed at driving meaningful improvements to the current standard of care for cancer patients.
About MiNK Therapeutics
MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery, development and commercialization of allogeneic invariant natural killer T cell (iNKT) therapies for the treatment of cancer and other immune-mediated diseases. MiNK is driving a pipeline of both native and engineered next-generation iNKT programs, with a platform designed to enable scalable and reproducible manufacturing for off-the-shelf delivery. The company is headquartered in New York, NY. For more information visit https://minktherapeutics.com/. Follow us on…
[ad_2]
Source story
